Usage Examples
- The ANDA cited the Orange Book RLD and included a Paragraph IV certification against the listed patents.
- The generic was rated AB in the Orange Book, so the pharmacy could substitute it automatically.
- Delisting the patent from the Orange Book opened the door to generic competition.
What is Orange Book?
Orange Book is FDA's published list of drug products approved as safe and effective under the Federal Food, Drug, and Cosmetic Act, paired with therapeutic equivalence codes and the patent and exclusivity information that governs generic entry.
Orange Book exists because generic competition needs a public reference point. An abbreviated application rides on a drug FDA has already approved, so applicants, state pharmacy boards, and courts all need one authoritative record of what is approved, what is interchangeable with what, and which patents stand in the way. Orange Book is that record.
Orange Book covers drug products approved on the basis of safety and effectiveness under the Federal Food, Drug, and Cosmetic Act, together with therapeutic equivalence evaluations for approved multisource prescription products and the patent information NDA holders must submit. Orange Book does not extend to biological products licensed under the Public Health Service Act, and it excludes process, packaging, metabolite, and intermediate patents by rule.
Orange Book gets used three ways. Generic and 505(b)(2) sponsors pull the reference product and every listed patent from it before drafting certifications. NDA holders feed it, submitting Form FDA 3542 within 30 days of approval. Pharmacists and state substitution laws read Orange Book therapeutic equivalence codes to decide whether one product can be dispensed for another.
Not to be confused with
- Purple Book
- the Purple Book covers biological products licensed under the Public Health Service Act, including biosimilars. Placement is decided by the statute a product was approved under, not by molecule size, so a large molecule approved under an NDA is not automatically a Purple Book entry.
- Drugs@FDA
- Drugs@FDA is the approval-history database holding approval letters, reviews, and labeling. The Orange Book is the list that carries therapeutic equivalence codes and patent and exclusivity data. Approval evidence lives in one; substitution and patent status live in the other.
- National Drug Code Directory
- the NDC Directory identifies packaged products in commercial distribution. Appearing there says nothing about approval status or therapeutic equivalence; only the Orange Book carries the FDA approval and equivalence determination.
- Reference Listed Drug
- an RLD is a single entry inside the Orange Book, the approved product one abbreviated application relies on. The Orange Book is the whole list; the RLD is the one row a specific ANDA points at.
The listing obligations fall on the NDA holder; the reading obligations fall on everyone downstream.
What you must do
- 1Submit patent information on the required FDA declaration form for each patent that claims the drug or a method of using the drug that is the subject of the NDA, and against which a claim of patent infringement could reasonably be asserted21 CFR 314.53(b)
- 2Withhold process patents, packaging patents, metabolite patents, and intermediate patents from that submission, since the regulation bars listing them21 CFR 314.53(b)
- 3File Form FDA 3542 within 30 days after approval of the NDA or supplement for each patent claiming the drug substance, the drug product, or an approved method of use21 CFR 314.53(c)
- 4Amend the NDA within 30 days of issuance for any patent granted after the NDA is filed but before it is approved21 CFR 314.53(c)
- 5Expect each properly submitted patent number and expiration date to be published in the list, along with the description of the method of use for every method-of-use patent21 CFR 314.53
- 6Read therapeutic equivalence codes as FDA's evaluation of approved multisource prescription products, issued as advice to state health agencies, prescribers, and pharmacists for drug product selectionOrange Book Preface, Therapeutic Equivalence Evaluations
Common mistakes
Submitting patents the regulation excludes
process, packaging, metabolite, and intermediate patents must not be submitted, yet they still get filed on the declaration form by counsel optimising for coverage. The listing does not survive challenge, it forces a correction to the NDA, and it buys none of the delay the sponsor was reaching for.
Missing the 30-day submission window
Form FDA 3542 is due within 30 days of NDA or supplement approval, and within 30 days of issuance for a patent granted between filing and approval. Miss it and the patent sits off the list while competitors draft certifications against a record that does not name it.
Searching the Orange Book for a biologic
a product licensed under the Public Health Service Act will never appear there, and teams that read the empty result as "not approved" waste diligence cycles and misjudge exclusivity. Check the Purple Book before concluding anything about a biological product.
When This Matters
- The ANDA cited the Orange Book RLD and included a Paragraph IV certification against the listed patents.
- The generic was rated AB in the Orange Book, so the pharmacy could substitute it automatically.
- Delisting the patent from the Orange Book opened the door to generic competition.
Frequently Asked Questions
The Orange Book lists drug products approved under the Federal Food, Drug, and Cosmetic Act; the Purple Book lists biological products licensed under the Public Health Service Act. The dividing line is the statute a product was approved under, not its size or complexity. Generic pathways reference the Orange Book; biosimilar pathways reference the Purple Book.
Related Use Cases
- Pharma Use Cases
Cut NDA and sNDA prep time by 60% with AI-assisted drafting and automated readiness checks
- Biotech Use Cases
Compress IND prep from 8-12 weeks to under 3 weeks with AI-assisted drafting and validation
- Regulatory Affairs Workflows
Cut regulatory intelligence tracking from 10+ hours/week to automated, real-time alerts
- CMC Workflows
Track ICH quality guidelines automatically and get alerts when changes impact your products
